Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study. Clin Drug Investig. 2011;31(7):493-505.
Pepe A, Rossi G, Bentley A, et al. Cost-utility analysis of three iron chelators used in monotherapy for the treatment of chronic iron overload in beta-thalassaemia major patients: An Italian perspective. Clin Drug Investig; 2017.
Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLoS One. 2013;8(12):e82662.
Ahmed J, Ahmad N, Jankharia B, Krishnan P, Merchant RH. Effect of deferasirox chelation on liver iron and total body iron concentration. Indian J Pediatrics. 2013;80(8):655-8.
Gomber S, Jain P, Sharma S, Narang M. Comparative efficacy and safety of oral iron chelators and their novel combination in children with thalassemia. Indian J Pediatrics. 2016;53(3):207-10.
Ho PJ, Tay L, Teo J, et al. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study). Eur J Haematol. 2017;98(2):97-105.
Merchant R, Ahmed J, Krishnan P, Jankharia B. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia. Indian J Pediatrics. 2012;49(4):281-5.
Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010;89(4):405-9.
Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica. 2011;96(1):48-54.
Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
Pepe A, Lombardi M, Positano V, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006;76(3):183-92.
Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41-7.
Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE((R)) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol. 2013;88(4):251-60.
Zachariah M, Tony S, Bashir W, Al Rawas A, Wali Y, Pathare A. Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience. Pediatric Hematol Oncol. 2013;30(2):104-12.
Saggar K, Sobti P. MRI Assessment of iron overload in thalassemia: an overview. Rivista Italiana di Medicina dell’Adolescenza-Volume. 2013;11(1).
Ambati SR, Randolph R, Mennitt K, Kleinert DA, Giardina P. Monitoring cardiac siderosis in patients with beta-thalassemia major on various chelation regimens. Blood. 2011;118(21):3177.
Borgna-Pignatti CA, Rugolotto SI, De Stefano P, Zhao HU, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi RO, Piga AN. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93.
Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Malcolm Walker J, Pennell DJ. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British J Haematol. 2004;127(3):348-55.
Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (Deferasirox). Blood. 2005;106(11):3600.
Maggio A, Vitrano A, Lucania G, Capra M, Cuccia L, Gagliardotto F, Pitrolo L, Prossomariti L, Filosa A, Caruso V, Gerardi C. Long‐term use of deferiprone significantly enhances left‐ventricular ejection function in thalassemia major patients. Am J Hematol. 2012;87(7):732-3.
Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-96.
Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332):516-20.
Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42(1):81-5.
Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clinical Therapeutics. 2007;29(5):909-17.
Fisher R. Large-scale study in thalassemia using biomagnetic liver susceptometry. InProc. 11th Int. Conf/Biomagnetism 1998.
Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO). InBlood 1997;90(10):1161.
- There are currently no refbacks.